Evista (Raloxifene) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 3, 2016 Category: Drugs & Pharmacology Source Type: news

Evista (raloxifene)
Title: Evista (raloxifene)Category: MedicationsCreated: 7/23/1998 12:00:00 AMLast Editorial Review: 9/30/2016 12:00:00 AM (Source: MedicineNet Menopause General)
Source: MedicineNet Menopause General - September 30, 2016 Category: Primary Care Source Type: news

Evista Blunts Symptoms in Women With Schizophrenia
(MedPage Today) -- No safety issues in small study, but thromboembolic risk remains concern (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 21, 2016 Category: Psychiatry Source Type: news

VIDEO: Advice varies for chemoprevention, genetic testing in invasive breast cancer
MIAMI – The message from major trials evaluating tamoxifen, raloxifene, and aromatase inhibitors for chemoprevention of invasive breast cancer got clearer with data from extended follow-up coming in.... (Source: Family Practice News)
Source: Family Practice News - March 12, 2016 Category: Primary Care Source Type: news

Raloxifene in Postmenopausal SchizophreniaRaloxifene in Postmenopausal Schizophrenia
Raloxifene improves negative symptoms in postmenopausal women with schizophrenia on antipsychotic treatment, a new study in 70 patients shows. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 16, 2015 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Raloxifene Fails to Affect Cognition in Alzheimer's Disease (CME/CE)
(MedPage Today) -- But subtle benefits can't be ruled out (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 5, 2015 Category: Geriatrics Source Type: news

No Cognitive Benefit of Raloxifene in Women with Alzheimer's No Cognitive Benefit of Raloxifene in Women with Alzheimer's
The selective estrogen receptor modulator failed to improve cognition in a small study of women with AD, although the possibility of a small cognitive benefit can't be excluded, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 5, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Hormone-Like Drug Doesn't Help Women With Alzheimer's: Study
Researchers find no benefits from raloxifene in those with mild to moderate dementia (Source: WebMD Health)
Source: WebMD Health - November 4, 2015 Category: Consumer Health News Source Type: news

The Estrogen Drug That Reduces Your Breast...
Evista (raloxifene) is a drug that has been used for treatment of osteoporosis in postmenopausal women. The FDA has also approved it for prevention of invasive breast cancer. Evista creates an estrogen blockade, which lowers the incidence of estrogen-sensitive breast cancer. Learn more about Evista - uses, side effects, and benefits. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - October 18, 2015 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Comparison of the Effects of the Selective Estrogen Receptor Modulators Ospemifene, Raloxifene, and Tamoxifen on Breast Tissue in Ex Vivo Culture
Explant tissue culture provides a model for studying the direct effects of steroid hormones, their analogs, and novel hormonally active compounds on normal freshly isolated human breast tissues (HBTs). For this purpose, pre- and postmenopausal HBTs can be maintained in this culture system. The results demonstrate that the morphological integrity of HBT explants can be maintained in tissue culture up to 2 weeks and expression of differentiation markers, steroid hormone receptors, proliferation and apoptosis ratios can be evaluated as a response to hormonal stimulation. This chapter describes an ex vivo culture model that we...
Source: Springer protocols feed by Biochemistry - October 12, 2015 Category: Biochemistry Source Type: news

Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol
The estrogen receptors (ERs) belong to the nuclear receptor superfamily, and as such act as ligand inducible transcription factors, mediating the effects of estrogens. However, their pharmacology is complex, having the ability to be differentially activated by ligands. Such ligands possess the ability to behave as either ER-agonists or ER-antagonists, depending on the cellular and tissue context, and have been termed Selective Estrogen Receptor Modulators (SERMs). Several SERMs have been identified with clinical relevance such as tamoxifen and raloxifene. Recently, 27-hydroxycholesterol has been characterized as the first ...
Source: Springer protocols feed by Biochemistry - October 11, 2015 Category: Biochemistry Source Type: news

Aurobindo Pharma gets US FDA nod for generic osteoporosis drug
Aurobindo Pharma has received approval from the US FDA to manufacture and market its generic version of Eli Lilly's Evista tablets used to treat and prevent osteoporosis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 29, 2015 Category: Pharmaceuticals Source Type: news

Some 'Benign' Breast Masses Pose Greater Cancer Risk Than We Thought
By Gene Emery (Reuters Health) - A type of "benign" mass found in the breast tissue of about 100,000 U.S. women each year poses a greater risk of cancer than previously thought, according to a new review. The mass is classified as atypical hyperplasia, or atypia. Most women who have it - and one out of 10 women who have a breast biopsy do - are usually told that their test result was benign, even though their cells seemed to be exhibiting some early characteristics of a tumor. Doctors may tell those women that they face an above-average risk of cancer so they need to be followed more closely,...
Source: Healthy Living - The Huffington Post - December 31, 2014 Category: Consumer Health News Source Type: news

One million women denied 7p breast cancer drug that can halve chance of developing disease
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news

One million women denied the 7p breast cancer drug that can halve chance of developing disease because of red tape
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news

Review Examines Efficacy and Safety of Osteoporosis Drugs (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Bisphosphonates, denosumab, teriparatide, and raloxifene all reduce risk for fracture relative to placebo in women with osteoporosis, according to a federally commissioned systematic review … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 9, 2014 Category: Primary Care Source Type: news

Revealing novel mode of action for osteoporosis drug
Raloxifene is a US Food and Drug Administration-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. X-ray studies revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 29, 2014 Category: Science Source Type: news

Revealing a novel mode of action for an osteoporosis drug
(DOE/Argonne National Laboratory) Raloxifene is a US Food and Drug Administration-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. X-ray studies revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2014 Category: Global & Universal Source Type: news

500,000 denied 7p-a-day breast cancer drug
Those with a family history of breast cancer should be offered Tamoxifen or the similar drug Raloxifene, which can cut their risk by 40 per cent. (Source: the Mail online | Health)
Source: the Mail online | Health - July 2, 2014 Category: Consumer Health News Source Type: news

Deirdre Connelly
President, North American Pharmaceuticals Deirdre Connelly joined GSK as President, North American Pharmaceuticals, on 9 February 2009.  She reports to Andrew Witty, Chief Executive Officer and is a member of GSK’s Corporate Executive Team. Prior to this, Deirdre was appointed President of US operations at Eli Lilly and Company in 2005.  Previously she was senior vice president for Human Resources for Lilly.  She had joined Lilly in 1983 as a sales representative and moved to San Juan as a marketing associate a year later.  After progressing through sales and marketing roles of increasing responsi...
Source: PHRMA - April 7, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news

Teva's Generic Evista Approved In The U.S.
Teva announced that its generic equivalent to Evista (raloxifene) 60 mg tablets has been approved in the U.S. The approval makes Teva’s generic version eligible for 180 days of marketing exclusivity. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 10, 2014 Category: Pharmaceuticals Source Type: news

Teva Announces Approval of Generic Evista(R) Tablets 60 mg in the United States
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (TEVA) announces the approval of the generic equivalent to Evista® (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product elig... Biopharmaceuticals, Generics, FDA, Product LaunchTeva Pharmaceutical, Evista, Raloxifene (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 4, 2014 Category: Pharmaceuticals Source Type: news

Evista (Raloxifene HCI) Lowers Risk of Invasive...
Evista (raloxifene) is a drug that has been used for treatment of osteoporosis in postmenopausal women. The FDA has also approved it for prevention of invasive breast cancer. Evista creates an estrogen blockade, which lowers the incidence of estrogen-sensitive breast cancer. Learn more about Evista - uses, side effects, and benefits. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 21, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Women who could benefit from medicine to prevent breast cancer often don't take them
Many new and potent medicines to prevent breast cancer have become available in the past 20 years. Surprisingly, many women—even those at high risk for the disease—are not taking advantage of these medicines, according to an article in the January 2014 issue of the Harvard Women's Health Watch. Drugs such as tamoxifen (Nolvadex), raloxifene (Evista), and exemestane (Aromasin) can reduce the odds of developing breast cancer for many women at high risk of developing breast cancer. "These drugs have been shown to prevent the occurrence of invasive and pre-invasive breast cancers," says Dr. Paul Goss, dir...
Source: New Harvard Health Information - December 20, 2013 Category: Consumer Health News Source Type: news

Anastrozole may cut breast cancer risk
Conclusion Overall, the study provides solid and believable evidence that anastrozole can reduce the number of new cases of breast cancer in postmenopausal women at higher than average risk of developing breast cancer. The study has many strengths, including its large sample size and robust study design. However, the study also has limitations to note. The results only apply to a specific group of postmenopausal women at a higher than average risk of developing breast cancer. "Higher risk" was defined using a number of very specific criteria. This means the results are not applicable to other groups of post...
Source: NHS News Feed - December 13, 2013 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Breast cancer drug 'halves likelihood of high-risk women developing disease'
Anastrozole must be made available on NHS immediately, say charities and authors of trial funded by Cancer Research UKA drug not yet available on the NHS has been found to be better at preventing breast cancer than those approved for use, leading to urgent calls for the National Institute for Health and Care Excellence to make it accessible immediately.The drug anastrozole has been found to halve the likelihood of high-risk women developing the disease and to have fewer side-effects, according to a study published on Thursday in the Lancet medical journal. The Ibis-II study, funded by Cancer Research UK and led by Queen Ma...
Source: Guardian Unlimited Science - December 12, 2013 Category: Science Authors: Alexandra Topping Tags: theguardian.com News Health Society Drugs The National Institute for Health and Care Excellence (Nice) UK news Breast cancer NHS Science Source Type: news

Dr. Timothy J. Garnett
Chief Medical Officer & SVP, Eli Lilly & CompanyDr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice-President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director Duloxetine SUI Team; and European...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news

Dr. Timothy J. Garnett, FRCOG, MFFP, FFPM
Chief Medical Officer & SVP, Development Center of Excellence, Eli Lilly & CompanyDr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice-President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news

Task Force issues final recommendations on medications for risk reduction of primary breast cancer in women
The United States Preventive Services Task Force (USPSTF) recommends against using medications such as tamoxifen or raloxifene for reducing the risk of primary breast cancer in average risk women, as the risks associated with these medications outweigh the potential benefits. Doctors should discuss the benefits and harms of these treatments and offer to prescribe them to women who are at high risk for breast cancer and low risk for adverse reactions. In high-risk populations, the benefits may outweigh the risks... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 25, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Discuss Chemoprevention With Women at Risk for Breast CancerDiscuss Chemoprevention With Women at Risk for Breast Cancer
The US Preventive Services Task Force (USPSTF) has finalized its guidelines on the use of tamoxifen and raloxifene to prevent breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Guidelines on Chemoprevention for Breast CancerNew Guidelines on Chemoprevention for Breast Cancer
The US Preventive Services Task Force (USPSTF) has finalized its guidelines on the use of tamoxifen and raloxifene to prevent breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Experts: Women at high risk of breast cancer should consider 2 drugs
WASHINGTON, Sept. 24 (UPI) -- Women with a higher-than-usual risk for breast cancer should consider taking tamoxifen or the osteoporosis drug raloxifene, a panel of U.S. experts advises. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 24, 2013 Category: Consumer Health News Source Type: news

Who Benefits from Breast Cancer Prevention Drugs? These Genes Might Tell
Researchers matched two gene variations previously unconnected to breast cancer with a positive response to long-term cancer prevention treatment using tamoxifen or raloxifene. Both medications are sometimes given to women who are at high risk of breast cancer, but the drugs can have side effects, including blood clots and increased risk of endometrial cancers. The variants are present in or nearby to genes that affect expression of the gene BRCA1, which is strongly associated with the development of breast cancer. Women with the beneficial version of the two variants were more than 5 times less likely than other high-risk...
Source: NIGMS Biomedical Beat - July 18, 2013 Category: Research Source Type: news

Eli Lilly Freezes Salaries as Patents Expire
Eli Lilly and Company is freezing salaries for most employees in 2014 to reduce costs. Officials said the company would also reduce bonuses paid out in 2015 for 2014 employee performances. "This is a difficult, but necessary decision. While we remain confident in our future, we continue to face the most significant challenges in our history. We expect to lose about 20 percent of our global revenue in 2014 because of the expiration of the Cymbalta and Evista patents in the U.S. While we've taken many actions to reduce costs and become a leaner organization, we must do more. We estimate these actions will enable us to ...
Source: PharmaManufacturing.com - July 18, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news

Doctors can prescribe preventive pill for breast cancer
NICE recommends tamoxifen or raloxifene for up to five years for 'at-risk' women Related items from OnMedicaNew genetic test detects early breast cancerWomen may be offered drug to prevent breast cancerSERMs ward off common breast cancer over long termNICE draft rejects everolimus for advanced breast cancerSecrets of tamoxifen mechanism uncovered (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 26, 2013 Category: UK Health Source Type: news

Chemoprevention of Breast Cancer Recommended in BritainChemoprevention of Breast Cancer Recommended in Britain
The National Institute of Clinical Excellence now recommends using tamoxifen and raloxifene in people at high risk for breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 25, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease. They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older. The updated guideline has also made changes t...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news

Tamoxifen and raloxifene: Daily pill a 'breakthrough' in the prevention of breast cancer
Hundreds of thousands of women will be prescribed a daily pill that can reduce their risk of getting breast cancer, in what campaigners have called a “game-changing” breakthrough in preventive care.     (Source: The Independent - Science)
Source: The Independent - Science - June 24, 2013 Category: Science Tags: Science Source Type: news

Tamoxifen and raloxifene: Women to be offered daily pill to prevent breast cancer
Hundreds of thousands of women will be prescribed a daily pill that can reduce their risk of getting breast cancer, in what campaigners have called a “game-changing” breakthrough in preventive care.     (Source: The Independent - Science)
Source: The Independent - Science - June 24, 2013 Category: Science Tags: Science Source Type: news

Gene Variations May Predict Response to Breast Cancer Prevention Therapies
Researchers from the Mayo Clinic have identified variants in two genes that result in a higher chance that tamoxifen or raloxifene will actually prevent breast cancer. More studies are needed, but if confirmed, women with these variants may be more likely to undergo the 5-year preventive regimen. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

Identifying Women Most Likely To Respond To Preventive Breast Cancer Therapy
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery. "Our findings are important because we identified genetic factors that could eventually be used to select women who should be offered the drugs for prevention," said James Ingle, M.D., an oncologist at Mayo Clinic. Dr... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 17, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Which Women Should Receive Preventive Breast Cancer Drugs?
A new study, published in the journal Cancer Discovery, revealed that genetic variations could be a key indicator of which women are likely and which are unlikely to benefit from tamoxifen or raloxifene for breast cancer prevention. James Ingle, M.D., an oncologist at the Mayo Clinic, who was part of the study, said that the findings are important "because we identified genetic factors that could eventually be used to select women who should be offered the drugs for prevention... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Tamoxifen: Gene Test May Predict Benefit (CME/CE)
(MedPage Today) -- Two genes may predict which women would benefit from breast cancer primary prevention with tamoxifen or raloxifene (Evista), analysis of the pivotal trials showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2013 Category: Hematology Source Type: news

Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - June 13, 2013 Category: Hospital Management Authors: Mayo Clinic Source Type: news

Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - June 13, 2013 Category: Research Authors: Mayo Clinic Source Type: news

Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 13, 2013 Category: Databases & Libraries Authors: Mayo Clinic Source Type: news

Genetic Markers Could Focus Breast Cancer ChemopreventionGenetic Markers Could Focus Breast Cancer Chemoprevention
Newly discovered genetic markers could be used to select which women would benefit most from chemoprevention with tamoxifen and raloxifene. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Newly Identified Markers May Predict Who Will Respond To Breast Cancer Prevention Therapy
Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. Women who have the favorable variations of these two SNPs are more likely to respond to prevention therapy, according to this study... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Genetic variations may help identify best candidates for preventive breast cancer drugs
(Mayo Clinic) Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2013 Category: Cancer & Oncology Source Type: news